Target intelligence / Profile preview

Poliovirus capsid D antigen (D-Ag)

Target
D-Ag
Molecular classification
Other, Viral protein, Viral antigen
01

Overview

Poliovirus capsid D antigen (also known as the native or N-antigen) is the conformationally native, infectious form of the poliovirus protein capsid. The capsid is an icosahedral structure composed of 60 copies of four viral structural proteins: VP1, VP2, VP3, and VP4. The D-antigen is the critical immunogenic component of inactivated polio vaccines (IPV), as it is the primary form capable of inducing the production of protective neutralizing antibodies in the host. In contrast, the non-infectious, empty, or heated capsid form is known as the C-antigen (or H-antigen), which lacks genomic RNA and does not elicit a protective neutralizing immune response. Quantification of D-antigen units (D-AgU) is the standard method for determining the potency and stability of IPV formulations during manufacturing. Vaccines targeting this antigen, such as IPOL and various combination vaccines (e.g., Pentacel, Vaxelis), have been highly successful in the global effort to eradicate poliomyelitis.

Other names
Poliovirus D-antigenPoliovirus native antigenPoliovirus N-antigenPoliovirus capsid protein D-antigenPoliovirus D antigen
02

Mechanism of action

Active immunization by inducing neutralizing antibodies against poliovirus serotypes 1, 2, and 3

03

Biological functions

Immune responseOther
04

Disease associations

Infection
05

Safety considerations

Injection site reactionsAllergic reactions to trace manufacturing components (e.g., neomycin, polymyxin B, streptomycin, formaldehyde)Anaphylaxis
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Neutralizing antibody titerSeroconversion rateD-antigen ELISA titer

Beyond the preview

Go deeper on Poliovirus capsid D antigen (D-Ag).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poliovirus capsid D antigen (D-Ag).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call